TY - JOUR
T1 - Better pandemic influenza preparedness through adjuvant technology transfer
T2 - Challenges and lessons learned
AU - Lemoine, Céline H.
AU - Nidom, Reviany V.
AU - Ventura, Roland
AU - Indrasari, Setyarina
AU - Normalina, Irine
AU - Santoso, Kuncoro Puguh
AU - Derouet, Francis
AU - Barnier-Quer, Christophe
AU - Borchard, Gerrit
AU - Collin, Nicolas
AU - Nidom, Chairul A.
N1 - Funding Information:
For this project, a research consortium was established within the scope of the Swiss Programme for Research on Global Issues for Development (r4d). This is a Swiss funding scheme which supports high-quality research projects that aim to provide solutions to global problems with a focus on collaborations between Swiss and LMIC organizations. One of the Swiss partners was the Vaccine Formulation Laboratory (VFL) at the University of Lausanne, today known as Vaccine Formulation Institute (VFI), an independent not-for-profit company. Briefly, the VFI supports the vaccine community with gaining wider access to adjuvant technologies and vaccine formulation know-how [35]. A second Swiss partner, the unit of Biopharmaceutical Sciences at the University of Geneva (UNIGE), is dedicated to the formulation, characterization, and testing of advanced drug and vaccine carrier systems. Over the last ten years, they have developed expertise covering protein drugs, DNA vaccines, novel adjuvants, and nanomedicines. The Indonesian partner was the Professor Nidom Foundation (PNF) with support from Airlangga University. The PNF is an Indonesian research and education organization that has extensive experience in the surveillance and characterization of influenza viruses. Research activities at the PNF include establishing recombinant influenza seed virus for improved vaccine virus yield and developing alternative cell-culture-derived virus propagation tools, using zebrafish primary cell cultures. An additional Indonesian collaborator of this project was PT Bio Farma, the largest vaccine manufacturer in Indonesia, who provided their expertise and support on vaccine production. PT Bio Farma is a state-owned vaccine producer and the only producer of human vaccines and anti-sera in Indonesia. In 2010–2015, PT Bio Farma was a technology transfer recipient through a project funded by the United States Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), in the context of a WHO international collaboration on technology transfer. Within this project the VFL transferred the know-how to PT Bio Farma for manufacturing an oil-in-water emulsion [32].
Funding Information:
Funding: This research was funded by the Swiss National Science Foundation (SNF) and Swiss Agency for Development and Cooperation (SDC) as a joint funding initiative called The Swiss Programme for Research on Global Issues for Development (r4d programme), grant number IZ07Z0_160923.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5
Y1 - 2021/5
N2 - Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature.
AB - Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature.
KW - Adjuvanted vaccines
KW - Global health
KW - Influenza
KW - Lessons learned
KW - Pandemic preparedness
KW - Technology transfer
UR - http://www.scopus.com/inward/record.url?scp=85105935254&partnerID=8YFLogxK
U2 - 10.3390/vaccines9050461
DO - 10.3390/vaccines9050461
M3 - Review article
AN - SCOPUS:85105935254
VL - 9
JO - Vaccines
JF - Vaccines
SN - 2076-393X
IS - 5
M1 - 461
ER -